Nobel-winning AIDS Researcher appreciates my discoveries about Pam3Cys Immune Suppression
Mort Zuckerman
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, the-...@nytimes.com, biz...@nytimes.com,
for...@nytimes.com, me...@nytimes.com, nati...@nytimes.com,
dv...@cdc.gov, brigidc...@optonline.net, tr...@hotmail.com,
illino...@aol.com, jle...@courant.com, tinaj...@yahoo.com,
jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, FalN...@aol.com,
brans...@comcast.net, vts...@comcast.net, o...@po.state.ct.us,
freet...@charter.net, scott....@po.state.ct.us,
govern...@po.state.ct.us, attorney...@po.state.ct.us,
randall...@usdoj.gov, Robert....@yale.edu
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, sidney_b...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com, wl-
edi...@sunshinepress.org, ly...@idsociety.org
Subject: Nobel-winning AIDS Researcher appreciates my discoveries
about Pam3Cys Immune Suppression
Date: Dec 18, 2008 10:53 AM
Nobel AIDS Researcher appreciates my (with Paul Duray's lead)
discoveries about Pam3Cys Immune Suppression
http://www.actionlyme.org/PAM3CYS_IMMUNE_SUPPRESSION.htm
and how that - Yale's bogus Lyme vaccine - related to the
HIV vaccine failures (OspA is stuck on an HIV vaccine,
because OspA - the Pam3Cys triacyl lipopeptide - is also
found in HIV gp120 and gp41.
America is not welcome, but the rest of the world is.
Kathleen M. Dickson
"The incredibly hard and rigorous work that *** Kathleen M. Dickson
*** did by herself has managed to accomplish has answered the
difficult questions of the mechanism and opened a new window into HIV/
AIDS. As a result, we have been able to attract individuals like Dr.
Montagnier, a Nobel Laureate and brilliant virologist to our team,
something we could have only dreamed when we started on this journey
years ago. It validates our work and clearly shows our progress into
the research community," said Monica Ord, SVP of Corporate Development
and Communications."
===========================
PRESS RELEASE
AIDS Nobel Laureate Joins Viral Genetics
Luc Montagnier Will Advise Firm Developing Immune-Based Therapies
Last update: 10:00 a.m. EST Dec. 18, 2008
SAN MARINO, Calif., Dec 18, 2008 (BUSINESS WIRE) -- Luc Montagnier, co-
winner of the 2008 Nobel Prize for Medicine and the co-discoverer of
the HIV virus, has joined Viral Genetics (VRAL:
viral genetics inc del com
News , chart , profile , more
Last: 0.01+0.00+20.00%
10:24am 12/18/2008
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
VRAL 0.01, +0.00, +20.0%) , a biotechnology company that discovers and
develops immune-based therapies.
Montagnier joins a current team of esteemed advisors with diverse
expertise to help guide Viral Genetics as it develops unique therapies
for HIV and other diseases of the immune system.
Dr. Montagnier, Nobel Prize winner 2008 for his role in the discovery
of HIV, said:
"While some preventive candidate vaccines failed to protect against
HIV infection, and since there is no treatment able to cure the
disease, it is important to come back to basic research and to explore
new ways of research and treatment such as those explored by Viral
Genetics. This is why I joined the Advisory Board of this Company."
The purpose of the Viral Genetics Advisors is to provide independent
wisdom and insight to assist Viral Genetics in the accomplishment of
its medical and scientific objectives by providing advice that is
consistent with best-in-class scientific and medical practices and
principles. Based on new information from ongoing AIDS and Lyme
disease studies being led by head of research Dr. M. Karen Newell,
PhD, new components of the mechanism of TNP, the Company's drug
compound, have been identified. Viral Genetics continues to
aggressively seek out the appropriate individuals in relevant fields
to assist as the studies continue to move forward. These will include
highly sought-after individuals in many diverse fields of research.
The existing group and new advisors to be added have come together in
an effort to spearhead Viral Genetics' promising new model of targeted
peptide therapies for AIDS and other immune disease as swiftly as
possible.
Dr. M. Karen Newell, head of Viral Genetics' latest research and
discoverer of TNP's mechanism stated, "We are looking forward to the
guidance of Dr. Montagnier in our efforts. He will not only help us in
our research efforts, but also to identify experts in the studies of
immune response genes and HIV, protein and peptide chemistry, cell
death and apoptosis, pharmaco-genomics and computational biology. We
look to augment our existing scientific advisory team with expertises
that will strengthen and accelerate our ability to return to clinical
trials - armed with a new and improved model, a newly identified
potential mechanism of action, and a biologic product with
characteristics of a novel, therapeutic vaccine strategy than has ever
been tried in the past."
"It is indeed an honor and a privilege to have someone as world-
renowned in the field of virology and AIDS research as Dr. Montagnier
join our organization," said Viral Genetics President and CEO Haig
Keledjian.
Dr. Montagnier is best known for his 1983 discovery of the human
immunodeficiency virus (HIV), which has been identified as the cause
of AIDS. This discovery led directly to the development of a test for
detecting the presence of HIV in blood samples. He has received more
than 20 major awards, including the Commandeur de la Legion d'Honneur,
the Lasker Award, the Gairdner Award, King Faisal Foundation
International Prize(known as the Arab Nobel Prize),and this year's
Nobel Prize in Physiology or Medicine awarded to him for the discovery
of HIV.
He is the co-founder of the World Foundation for AIDS Research and
Prevention and co-directs the Program for International Viral
Collaboration.
As President of the World Foundation for Aids Research and Prevention,
he has co-founded two centers for the prevention, treatment, research
and diagnosis of AIDS patients in Ivory Coast and Cameroon.
Viral Genetics continues to study TNP, a mixture of peptides derived
from thymic histones, to research HIV/AIDS. The results of six
international human clinical trials of a TNP-based drug showed reduced
viral load and clinical improvement. During subsequent in vitro
research, the study group found that individual peptides in the TNP
mixture can bind to antigen-presenting cells and may be able to
redirect the immune response.
The study group has discovered, and will continue to search for,
peptides that will bind with high affinity to the greatest number of
molecules encoded by MHC alleles (genes) within a population. The MHC
genes encode molecules that are expressed on antigen presenting cells.
The group has finished preliminary studies, and is currently testing
candidate peptides in a number of in vitro and in vivo animal models
that it believes will provide proof-of-concept studies for both HIV as
well as other diseases.
To uncover the mechanism of action responsible for improvement in
previous international clinical trials of TNP, the active components
had to be identified and synthesized to purity. The purified peptides
then had to be, and will continue to be, tested for activity, safety,
and efficacy. As a result, Viral Genetics has uncovered evidence for a
likely mechanism of action using its targeted peptide approach. The
goal of the study is to obtain an Investigational New Drug application
for testing the newly identified and synthesized peptides or targeted
peptides that can appropriately redirect the immune response to HIV.
"The incredibly hard and rigorous work that Dr. Newell and her team
have managed to accomplish has answered the difficult questions of the
mechanism and opened a new window into HIV/AIDS. As a result, we have
been able to attract individuals like Dr. Montagnier, a Nobel Laureate
and brilliant virologist to our team, something we could have only
dreamed when we started on this journey years ago. It validates our
work and clearly shows our progress into the research community," said
Monica Ord, SVP of Corporate Development and Communications.
Dr. Montagnier will be joining the group of current esteemed advisors
which include:
C. Everett Koop. In February 1981, President Reagan appointed Dr. Koop
as Deputy Assistant Secretary for Health. On January 1982, when he was
sworn in by the Senate as U.S. Surgeon General, AIDS was a deadly
enigma. At the direct request of President Reagan in 1986, Dr. Koop
prepared the first national report on AIDS.
Dr Eric Rosenberg. Dr. Rosenberg has been co-chair, co-principal
investigator, and principal investigator of clinical trials focused on
HIV treatment, and has been the beneficiary of several NIH awards. Dr.
Rosenberg is an Assistant Professor of Medicine at Harvard Medical
School, where he has been appointed in various academic capacities
since 1995, and is a Staff Physician at the Massachusetts General
Hospital in Boston, where he has also been appointed since 1995.
Marshal Phelps who is currently Corporate Vice President for IP Policy
and Strategy for Microsoft. In this position, Mr. Phelps is
responsible for establishing global policy and strategy for
Microsoft's intellectual property, and interfacing with governments
and technology companies about intellectual property issues.
Richard Gerstner. Gerstner spent several years as President and CEO of
Telular Corporation, a wireless communication company he took public
in the 1990s. Prior to that, he spent 32 years at IBM in several
capacities including 10 years as a Corporate Vice President during
which he served as Chief Planning Officer, Head of the Asia/Pacific
region located in Tokyo and Group Executive of IBM Personal Computers,
and most recently as head of IBM's PC Group
Viral Genetics, Inc. is a biotechnology company that discovers and
develops immune-based therapies for HIV and AIDS using its thymus
nuclear protein compound (TNP). The company recently entered into an
Exclusive License Agreement with the University of Colorado and V-Clip
Pharmaceuticals (a subsidiary of the Company) to license technology
developed by M. Karen Newell, PhD that appears to explain TNP and
provide a means to optimize therapies based on TNP for future clinical
trials. TNP may have other potential applications for other
infectious, autoimmune, and immunological deficiency diseases that the
company intends to study in the future. Viral Genetics believes that
its investigational HIV/AIDS drug based on TNP, called VGV-1,
represents a unique approach to treating HIV due to the apparently
novel mechanism, low toxicity profile, simple dosing regimen, and
short-course of treatment. As a type of immune-based therapy, it
focuses on boosting the immune system to allow the body to fight HIV
more efficiently. VGV-1 has been studied in five human clinical trials
for the treatment of HIV/AIDS. More information is available online at
www.viralgenetics.com.
This news release contains forward-looking statements that involve
risks and uncertainties associated with financial projections,
budgets, milestone timelines, clinical development, regulatory
approvals, and other risks described by Viral Genetics, Inc. from time
to time in its periodic reports filed with the SEC. VGV-1 is not
approved by the US Food and Drug Administration or by any comparable
regulatory agencies elsewhere in the world. While Viral Genetics
believes that the forward-looking statements and underlying
assumptions contained therein are reasonable, any of the assumptions
could be inaccurate, including, but not limited to, the ability of
Viral Genetics to establish the efficacy of VGV-1 in the treatment of
any disease or health condition, the development of studies and
strategies leading to commercialization of VGV-1 in the United States,
the obtaining of funding required to carry out the development plan,
the completion of studies and tests on time or at all, and the
successful outcome of such studies or tests. Therefore, there can be
no assurance that the forward-looking statements included in this
release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included
herein, the forward-looking statements should not be regarded as a
representation by Viral Genetics or any other person that the
objectives and plans of Viral Genetics will be achieved.
SOURCE: Viral Genetics
Viral Genetics
Haig Keledjian, 626-334-5310
Copyright Business Wire 2008 End of Story